With a blend of scientific excellence, public-private collaboration, and strong institutional support, the region is positioning itself as a strategic gateway for biotech and health innovation — not only within Europe, but also as a bridge to Latin America and beyond.
Today, biotech represents one of the most dynamic and high-potential areas of Madrid’s broader innovation ecosystem. For investors, startups, and global companies alike, the message is clear: Madrid is open for biotech business.
A Sector Backed by Science and Scale
At the heart of Madrid’s biotech strength is its world-class scientific infrastructure. The region is home to over 300 biotech companies, with a significant focus on health-related applications such as diagnostics, therapeutics, and pharmaceutical research.
These firms are supported by a dense network of top-ranked universities, research centres, and teaching hospitals, many of which are at the forefront of applied biomedical science. Institutions like the Hospital Universitario La Paz, CNIO (National Cancer Research Centre), and Carlos III Health Institute are not only global leaders in their fields — they also work closely with the private sector to turn research into real-world solutions.
Add to this a growing pool of highly skilled professionals in life sciences, bioengineering, and data analytics, and it’s no surprise that biotech is now one of the region’s fastest-growing innovation sectors.
A Magnet for Investment
Madrid’s biotech sector is increasingly attracting the attention of domestic and international investors — and for good reason.
In recent years, the region has seen a surge in venture capital activity, particularly in early-stage biotech and healthtech startups. Firms working in areas such as gene therapy, precision medicine, and AI-powered diagnostics are securing funding rounds with increasing frequency — a sign that Madrid is not just producing research, but commercialising it at pace.
Public funding and institutional support also play a key role. Through regional and national programmes, biotech ventures in Madrid can access a variety of tax incentives, R&D grants, and internationalisation support, making it easier for innovators to scale and compete on the global stage.
Invest in Madrid, the regional agency dedicated to attracting and supporting FDI of international businesses into Madrid, is actively working to connect investors with opportunities in the biotech space — offering tailored assistance, regulatory guidance, and market insights to help navigate the local landscape.
The Power of Clusters and Collaboration
One of Madrid’s core strengths lies in its collaborative ecosystem. The region is home to several bioclusters and innovation parks — including Madrid Science Park, TecnoGetafe, and Alcobendas’ Biotech Hub — that bring together startups, corporates, researchers, and investors under one roof.
These innovation centres provide not just physical infrastructure, but a framework for knowledge sharing, co-development, and cross-sector innovation. By fostering a culture of openness and shared purpose, Madrid is creating an environment where biotech ventures can grow with speed and resilience.
Furthermore, Madrid’s position as a business and policy capital gives biotech firms direct access to national regulators, health authorities, and public procurement pathways — an advantage few other regions can offer.
Gateway to Europe, and to LATAM
Strategically located at the crossroads of Europe and Latin America, Madrid offers investors and companies a unique platform to expand internationally. With its excellent transport infrastructure, multilingual workforce, and long-standing economic and cultural ties to the region, Madrid is ideally positioned as a launchpad into key Latin American markets — particularly Brazil, Colombia, and Mexico, which together account for a significant share of the region’s health and biotech activity.
This strategic connectivity is especially valuable in biotech, where clinical trial design, regulatory alignment, and market entry strategies often benefit from operating across multiple jurisdictions. Spain’s linguistic and regulatory familiarity with LATAM markets allows companies based in Madrid to bridge European innovation with Latin American market demand more efficiently.
Increasingly, biotech firms from Colombia and Mexico are choosing Madrid as their European base of operations, attracted by EU market access, shared language, and institutional support. Conversely, Spanish and European biotech companies are using Madrid to facilitate expansion into Brazil’s growing life sciences sector, engage in collaborative research partnerships, and structure licensing agreements or joint ventures across the region.
For companies looking to scale internationally, Madrid offers a unique dual advantage: a strong foothold in Europe, and a direct, culturally attuned gateway to some of LATAM’s most promising healthcare and biotech markets.
A Future Built on Innovation
As the global demand for health innovation continues to rise, Madrid is doubling down on its commitment to biotech as a pillar of sustainable economic growth. New initiatives focused on digital health, biomanufacturing, and advanced therapeutics are already underway — supported by ambitious government targets and an increasingly mature investor ecosystem. The region’s goal is clear: to become a reference point for biotech excellence in Southern Europe. For investors looking for high-growth potential, strategic location, and innovation-driven value, Madrid’s biotech sector offers a compelling proposition.